Source of this article and featured image is Wired Science. Description and key fact are generated by Codevision AI system.
A fentanyl vaccine is undergoing its first major trial in the Netherlands, aiming to prevent overdose deaths. Developed by ARMR Sciences, the vaccine uses antibodies to block fentanyl from reaching the brain. Fentanyl’s extreme potency makes it a leading cause of overdose deaths, especially among young adults. The trial, starting in 2026, will test safety and effectiveness in healthy adults. Researchers hope the vaccine could shift overdose prevention strategies by offering long-term protection.
Key facts
- The trial, led by ARMR Sciences, will begin in early 2026 in the Netherlands.
- The vaccine uses a carrier protein to stimulate antibody production against fentanyl.
- It aims to block fentanyl from entering the brain, preventing respiratory failure and overdose.
- Animal studies showed up to 98% effectiveness in blocking fentanyl’s effects.
- The vaccine is part of broader efforts to address the opioid epidemic and reduce overdose deaths.
TAGS:
#addiction treatment #biomedical innovation #drug trials #fentanyl vaccine #naloxone #opioid addiction #opioid epidemic #overdose prevention #public health #vaccine development
